FP 02.2

Drug Profile

FP 02.2

Alternative Names: FP 02; FP-02-2; FP02.2; Hepsyn-B™; HepTcell

Latest Information Update: 26 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Targeting Systems
  • Developer Altimmune
  • Class Hepatitis B vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 21 Dec 2017 Preliminary efficacy and adverse events data from a phase I trial in Hepatitis B released by Altimmune
  • 30 Sep 2017 Altimmune completes enrolment in a phase I trial for Hepatitis B in United Kingdom and South Korea before September 2017
  • 01 Sep 2015 Vaxin is now called Altimmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top